Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pepinemab antibody blockade of SEMA4D in early Huntington’s disease: a randomized, placebo-controlled, phase 2 trial
Andrew Feigin, Elizabeth E. Evans, Terrence L. Fisher, et al.
Nature Medicine (2022) Vol. 28, Iss. 10, pp. 2183-2193
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Role of neuroinflammation in neurodegeneration development
Weifeng Zhang, Dan Xiao, Qinwen Mao, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 506
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification
Jeffrey L. Cummings, Amanda M. Leisgang Osse, Jefferson W. Kinney
Drugs (2023) Vol. 83, Iss. 15, pp. 1387-1408
Open Access | Times Cited: 63
From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington’s Disease Research
Andrew Jiang, Renée R. Handley, Klaus Lehnert, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 16, pp. 13021-13021
Open Access | Times Cited: 53
Huntington’s Disease: Complex Pathogenesis and Therapeutic Strategies
Huichun Tong, Tianqi Yang, Shuying Xu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 3845-3845
Open Access | Times Cited: 19
Alzheimer’s disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy?
Daniela Melchiorri, Sara Merlo, Benjamin Micallef, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 24
Pathogenesis, Diagnostics, and Therapeutics for Alzheimer's Disease: Breaking the Memory Barrier
Pushpa Tryphena Kamatham, Rashi K. Shukla, Dharmendra Kumar Khatri, et al.
Ageing Research Reviews (2024) Vol. 101, pp. 102481-102481
Open Access | Times Cited: 11
A genome‐wide association meta‐analysis of all‐cause and vascular dementia
Bernard Fongang
Alzheimer s & Dementia (2024) Vol. 20, Iss. 9, pp. 5973-5995
Open Access | Times Cited: 9
Huntington’s Disease: Latest Frontiers in Therapeutics
Joseph Saade, Tiago Mestre
Current Neurology and Neuroscience Reports (2024) Vol. 24, Iss. 8, pp. 255-264
Closed Access | Times Cited: 8
Oligodendrocyte pathology in Huntington’s disease: from mechanisms to therapeutics
Costanza Ferrari Bardile, Carola I. Radulescu, Mahmoud A. Pouladi
Trends in Molecular Medicine (2023) Vol. 29, Iss. 10, pp. 802-816
Closed Access | Times Cited: 16
Inflammation and Huntington’s disease- a neglected therapeutic target?
Sophie E. Field, Annabel J. Curle, Roger A. Barker
Expert Opinion on Investigational Drugs (2024) Vol. 33, Iss. 5, pp. 451-467
Open Access | Times Cited: 5
Semaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity
Elizabeth E. Evans, Vikas Mishra, Crystal Mallow, et al.
Journal of Neuroinflammation (2022) Vol. 19, Iss. 1
Open Access | Times Cited: 27
Genetic topography and cortical cell loss in Huntington's disease link development and neurodegeneration
Carlos Estevez‐Fraga, André Altmann, Christopher S. Parker, et al.
Brain (2023) Vol. 146, Iss. 11, pp. 4532-4546
Open Access | Times Cited: 14
CCR2+ monocytes promote white matter injury and cognitive dysfunction after myocardial infarction
Edward B. Thorp, Mallory Filipp, Maria Dima, et al.
Brain Behavior and Immunity (2024) Vol. 119, pp. 818-835
Closed Access | Times Cited: 5
Plexins: Navigating through the Neural Regulation and Brain Pathology
Ariba Khan, Poonam Sharma, Swati Dahiya, et al.
Neuroscience & Biobehavioral Reviews (2025), pp. 105999-105999
Closed Access
Downregulation of N6-Methyladenosine (m6A) Methylation of Sema4D mRNA Contributes to Treg Dysfunction and Allograft Rejection
Yanzhuo Liu, Qiang Fu, Maozhu Yang, et al.
American Journal of Transplantation (2025)
Closed Access
Semaphorin 3s signaling in the central nervous system: Mechanisms and therapeutic implication for brain diseases
Ya-Ping Lu, Yiling Luo, Zhouyue Wu, et al.
Pharmacology & Therapeutics (2025), pp. 108800-108800
Closed Access
The Role of Genetic, Environmental, and Dietary Factors in Alzheimer’s Disease: A Narrative Review
Beyza Mertaş, İffet İpek Boşgelmez
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1222-1222
Open Access
Exploring immunotherapeutic strategies for neurodegenerative diseases: a focus on Huntington’s disease and Prion diseases
Abhiyanta Mukherjee, Soumojit Biswas, Ipsita Roy
Acta Pharmacologica Sinica (2025)
Closed Access
Pepinemab: a SEMA4D antagonist for treatment of Huntington’s and other neurodegenerative diseases
Andrew Feigin, Elizabeth E. Evans, Terrence L. Fisher, et al.
Expert Opinion on Investigational Drugs (2025)
Closed Access
Smoking aggravates neovascular age-related macular degeneration via Sema4D-PlexinB1 axis-mediated activation of pericytes
Kai He, Dong Xue, Tian-Jing Yang, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Rare Diseases, Spotlighting Amyotrophic Lateral Sclerosis, Huntington’s Disease, and Myasthenia Gravis: Insights from Landscape Analysis of Current Research
Kavita A. Iyer, Rumiana Koynova, Janet M. Sasso, et al.
Biochemistry (2025)
Closed Access
Huntington’s Disease Clinical Trials Corner: November 2022
Carlos Estevez‐Fraga, Sarah J. Tabrizi, Edward J. Wild
Journal of Huntington s Disease (2022) Vol. 11, Iss. 4, pp. 351-367
Open Access | Times Cited: 17
Emerging antibody-based therapies for Huntington’s disease: current status and perspectives for future development
Anamaria Jurcău, Aurel Simion, Maria Carolina Jurcău
Expert Review of Neurotherapeutics (2024) Vol. 24, Iss. 3, pp. 299-312
Closed Access | Times Cited: 3
Current clinical trials of new therapeutic agents for Huntington's disease
Blair R. Leavitt
Elsevier eBooks (2024), pp. 571-589
Closed Access | Times Cited: 3
Neuroimaging to Facilitate Clinical Trials in Huntington’s Disease: Current Opinion from the EHDN Imaging Working Group
Nicola Z. Hobbs, Marina Papoutsi, Aline Delva, et al.
Journal of Huntington s Disease (2024) Vol. 13, Iss. 2, pp. 163-199
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top